Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab Long-term Safety in CVD (FOURIER OLE)
NCT03080935Phase 3Terminated
- Sponsor
- Amgen
- Start
- Mar 2017
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of evolocumab in dyslipidemia, cardiovascular disease (CVD), sponsored by Amgen. Started Mar 2017; status: terminated.
02
Drugs
evolocumab
03
Conditions
dyslipidemiacardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT03080935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03080935.